

NOW ENROLLING IN MELANOMA




PHASE 3 (NCT03635983)

PIVOT IO 001: Beppegaldesleukin with nivolumab in patients with unresectable or metastatic melanoma

A randomized, open-label study of bepegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients with previously untreated, unresectable or metastatic melanoma¹⁻³

ENROLL NOW

Scan here to find out more about this clinical study at ClinicalTrials.gov



Beppegaldesleukin is an investigational CD122-preferential IL-2-pathway agonist⁴

Nivolumab is a PD-1 blocking antibody⁵

⁴Randomization is stratified by PD-L1 status, BRAF status, and AJCC stage (8th edition).

AJCC, American Joint Committee on Cancer; BEMPEG, bepegaldesleukin (NKTR-214); CBR, clinical benefit rate; DOR, duration of response; IL-2, interleukin-2; NIVO, nivolumab; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; TTR, time to treatment response.

1. [ClinicalTrials.gov. NCT03635983](https://clinicaltrials.gov/ct2/show/NCT03635983). <https://clinicaltrials.gov/ct2/show/NCT03635983>. Accessed March 10, 2021; 2. Khushalani NI, et al. Presented at: ASCO; May 31–June 4, 2019; Chicago, IL; 3. Khushalani NI, et al. *Future Oncol* 2020;16:2165–2175; 4. Bentebibel SE, et al. *Cancer Discov* 2019;9:711–21; 5. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: January 2021).

ACTIVE CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB


NEKTAR

Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverages two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

FIND OUT MORE

Scan here to discover more about BEMPEG at Nektar.com



^aNeoadjuvant and adjuvant setting.

BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab; R/R, relapsed/refractory

FOR EDUCATIONAL PURPOSES ONLY.

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard, South San Francisco, California 94158. Copyright Nektar Therapeutics © 2021. All rights reserved.